AOR-ESG
Aorticlab - ESG Impact assessment
Scheda del progetto
Aorticlab, which is close to the launch of FLOWer and clinical trials of Gemini, aims to enhance its business and social sustainability. Through the service with Brains Capital, it intends to assess and improve ESG impacts, prepare for becoming a Benefit or B-Corp Company and ensure gender equality. Objectives include developing corporate awareness, implementing ESG improvement actions, and preparing for corporate transformation and gender equality certification.
Contact:
Franco Osta
Consulting activities for measuring and quantifying ESG impact and developing the related strategic plan, including guidance for the transformation into a Benefit Corporation and/or B-Corp, and compliance with Gender Equality requirements with the aim of obtaining the corresponding certification.
Aorticlab stands out for its commitment to measuring and certifying social and environmental impact, as well as gender equality, strengthening its positioning in the biomedical sector. This innovative approach allows the company to demonstrate its dedication to achieving the goals of the UN strategic agenda, enhancing its innovation and competitiveness, and attracting new investors and business partners. Additionally, the use of digital tools and the adoption of advanced technologies during the service enable in-depth analysis and effective updates, reducing time, costs, and environmental impact.
The measurement and recognition of Aorticlab’s social and environmental impact, including gender equality, through the preparation of a sustainability report and other disclosures, will make the company more attractive to clients, investors, and patients. This will lead to continuous improvement in business processes and internal know-how, a competitive advantage over rivals, increased competitiveness nationally and internationally, and position Aorticlab as a benchmark for biomedical companies in terms of result transferability and best practices.